Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SAVA Cassava Sciences Inc

Market Closed 12-12 16:00:00 EST

2.93

-0.22

-6.98%

盘后3.00

+0.07+2.39%

19:59 EST

High3.20	Low2.93	Vol860.52K
Open3.16	D1 Closing3.15	Amplitude8.57%
Mkt Cap141.54M	Tradable Cap127.38M	Total Shares48.31M
T/O2.62M	T/O Rate1.98%	Tradable Shares43.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SAVA","market":"US","secType":"STK","nameCN":"Cassava Sciences Inc","latestPrice":2.93,"timestamp":1765573200000,"preClose":3.15,"halted":0,"volume":860524,"hourTrading":{"tag":"盘后","latestPrice":3,"preClose":2.93,"latestTime":"19:59 EST","volume":10641,"amount":31471.7812,"timestamp":1765587588285},"delay":0,"floatShares":43475193,"shares":48307896,"eps":-2.197613,"marketStatus":"Market Closed","change":-0.22,"latestTime":"12-12 16:00:00 EST","open":3.16,"high":3.2,"low":2.93,"amount":2618576.7693624,"amplitude":0.085714,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.197613,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.15,"preHourTrading":{"tag":"盘前","latestPrice":3.22,"preClose":3.15,"latestTime":"09:27 EST","volume":3559,"amount":11396.2077026,"timestamp":1765549658802},"postHourTrading":{"tag":"盘后","latestPrice":3,"preClose":2.93,"latestTime":"19:59 EST","volume":10641,"amount":31471.7812,"timestamp":1765587588285},"volumeRatio":1.322360937926204,"impliedVol":1.2474,"impliedVolPercentile":0.728},"requestUrl":"/m/hq/s/SAVA/wiki","defaultTab":"wiki","newsList":[{"id":"2588973046","title":"BRIEF-Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588973046","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588973046?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:51","pubTimestamp":1764766305,"startTime":"0","endTime":"0","summary":"BRIEF-Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC FilingDec 3  - Cassava Sciences Inc SAVA.O:CASSAVA SCIENCES INC - FDA REQUIRES ADDITIONAL INFORMATION FROM CASSAVA FOR CLINICAL STUDY - SEC FILINGCASSAVA SCIENCES INC - PREPARES TO INITIATE PROOF-OF-CONCEPT STUDY IN FIRST HALF OF 2026 FOR SIMUFILAM - SEC FILINGCASSAVA SCIENCES INC - EXPECTS FORMAL LETTER FROM FDA DETAILING ISSUES ON CLINICAL TRIAL FOR SIMUFILAM - SEC FILINGSource text: [ID:n0001437749-25-036710]Further company coverage: SAVA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4007","BK4588","BK4585","SAVA"],"gpt_icon":0},{"id":"2588048157","title":"Cassava Sciences Faces FDA Request for More Data on Simufilam Epilepsy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588048157","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588048157?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:27","pubTimestamp":1764761268,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has submitted an investigational new drug  application to the U.S. Food and Drug Administration  for a proposed proof-of-concept clinical trial of simufilam in tuberous sclerosis complex -related epilepsy. The FDA has requested additional information from the company to assess potential risks and support the initiation of the study. Cassava Sciences expects to receive a formal letter from the FDA detailing the required steps to address these issues and plans to work collaboratively with the agency, aiming to begin the trial in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Ga","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL9d5w2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SAVA","BK4585","BK4007","BK4547"],"gpt_icon":0},{"id":"2586409354","title":"Director Robert Eugene Anderson Jr. acquires common shares of Cassava Sciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2586409354","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586409354?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:06","pubTimestamp":1764104812,"startTime":"0","endTime":"0","summary":"Robert Eugene Anderson Jr., a director of Cassava Sciences Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDLCDWBc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Robert Eugene Anderson Jr. acquires common shares of Cassava Sciences Inc","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","BK4547","SAVA","BK4588"],"gpt_icon":0},{"id":"2586640692","title":"Cassava Sciences Gains on Insider Buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2586640692","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586640692?lang=en_us&edition=fundamental","pubTime":"2025-11-26 04:45","pubTimestamp":1764103539,"startTime":"0","endTime":"0","summary":"Cassava Sciences (SAVA) climbed as much as 12.1% intraday on Tuesday after a filing showed chief executive officer Richard Barry bought 150,000 shares on Nov. 20 for about $414,000. He now indirectly controls 938,060 shares.Price: 3.08, Change: +0.18, Percent Change: +6.03","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4007","BK4547","BK4585","SAVA"],"gpt_icon":0},{"id":"2586949086","title":"Cassava Sciences CEO Richard Barry Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586949086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586949086?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:02","pubTimestamp":1764018167,"startTime":"0","endTime":"0","summary":"Richard Barry, President & CEO, reported an acquisition of common shares of Cassava Sciences Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL2SwLgq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cassava Sciences CEO Richard Barry Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4547","SAVA","BK4585"],"gpt_icon":0},{"id":"2585167086","title":"Cassava Sciences CEO Makes Bold Move with Major Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167086","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167086?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:12","pubTimestamp":1763691149,"startTime":"0","endTime":"0","summary":"New insider activity at Cassava Sciences ( ($SAVA) ) has taken place on November 20, 2025. President & CEO Richard Barry has made a significant inv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/cassava-sciences-ceo-makes-bold-move-with-major-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/cassava-sciences-ceo-makes-bold-move-with-major-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BK4585","BK4007","BK4588","SAVA"],"gpt_icon":0},{"id":"2585165511","title":"Cassava Sciences CEO Richard Barry Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585165511","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585165511?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:52","pubTimestamp":1763679153,"startTime":"0","endTime":"0","summary":"Richard Barry, President & CEO of Cassava Sciences Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL2LPSzN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cassava Sciences CEO Richard Barry Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA","BK4007","BK4588","BK4547","BK4585"],"gpt_icon":0},{"id":"2583696655","title":"BRIEF-Cassava Sciences To Offer Securities Up To $200 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583696655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583696655?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:07","pubTimestamp":1763032054,"startTime":"0","endTime":"0","summary":"BRIEF-Cassava Sciences To Offer Securities Up To $200 MillionNov 13 (Reuters) - Cassava Sciences Inc SAVA.O:CASSAVA SCIENCES INC - TO OFFER SECURITIES UP TO $200 MILLION - SEC FILINGFurther company coverage: SAVA.O ((reuters.briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4007","BK4585","SAVA","BK4588"],"gpt_icon":0},{"id":"2583449569","title":"Cassava Sciences Inc - Enters 'at the Market Offering' of up to $50 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583449569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583449569?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:07","pubTimestamp":1763032026,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP106:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SAVA","BK4547","BK4585","BK4588","BK4007"],"gpt_icon":0},{"id":"2583531199","title":"Cassava Sciences Reports Q3 2025 Financials and Advances Simufilam","url":"https://stock-news.laohu8.com/highlight/detail?id=2583531199","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583531199?lang=en_us&edition=fundamental","pubTime":"2025-11-13 11:59","pubTimestamp":1763006391,"startTime":"0","endTime":"0","summary":"Cassava Sciences ( ($SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors. Cass...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cassava-sciences-reports-q3-2025-financials-and-advances-simufilam?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cassava-sciences-reports-q3-2025-financials-and-advances-simufilam?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BK4007","SAVA","BK4588","BK4585"],"gpt_icon":0},{"id":"2582715963","title":"Cassava Sciences Q3 net loss narrows, beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2582715963","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582715963?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:10","pubTimestamp":1762953004,"startTime":"0","endTime":"0","summary":"Cassava Sciences Q3 net loss narrows, beats expectationsOverviewCassava Sciences Q3 net loss narrows to $10.8 mln, beating analyst expectationsCompany advancing simufilam for TSC-related epilepsy, stu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAVA","BK4588","BK4585","BK4547","BK4007"],"gpt_icon":0},{"id":"2582763379","title":"Cassava Sciences posts Q3 net loss of $10.8 million on $106.1 million cash reserves","url":"https://stock-news.laohu8.com/highlight/detail?id=2582763379","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582763379?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:02","pubTimestamp":1762952571,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. reported cash and cash equivalents of $106.1 million with no debt as of September 30, 2025, compared to $128.6 million at the end of 2024. Net loss for the third quarter of 2025 was $10.8 million, or $0.22 per share, down from a net loss of $27.9 million, or $0.58 per share, for the same period in 2024. Net cash used in operations during the first nine months of 2025 was $22.5 million. The company estimates cash at year-end 2025 in the range of $92 to $96 million. Business developments include preparations for a proof-of-concept study of Simufilam in TSC-related epilepsy expected to begin in the first half of 2026, a license agreement with Yale University, and appointments of Joseph Hulihan, MD, as Chief Medical Officer and Dawn C. Bir as Independent Director.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL4GLDlm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","BK4007","IE00B3QW5Z07.USD","SAVA","BK4588","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","BK4547","LU0314104364.USD"],"gpt_icon":0},{"id":"2582037926","title":"BRIEF-Cassava Sciences Q3 Basic EPS USD -0.22","url":"https://stock-news.laohu8.com/highlight/detail?id=2582037926","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582037926?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952457,"startTime":"0","endTime":"0","summary":"BRIEF-Cassava Sciences Q3 Basic EPS USD -0.22\n\n\nNov 12 (Reuters) - Cassava Sciences Q3 operating expenses USD 11.86 million.\n\nQ3 net income USD -10.807 million\nQ3 EPS USD -0.22\nQ3 operating income USD -11.86 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX73D92F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","SAVA","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2582277371","title":"Cassava Reports Q3 2025 Financials Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582277371","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582277371?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952400,"startTime":"0","endTime":"0","summary":"Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186208/8339/en/Cassava-Reports-Q3-2025-Financials-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4588","BK4585","CNS","BK4135","BK4007","SAVA"],"gpt_icon":0},{"id":"2580214218","title":"Cassava Sciences Inc  expected to post a loss of 27 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580214218","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580214218?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:52","pubTimestamp":1762181547,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc  expected to post a loss of27cents a share - Earnings Preview Cassava Sciences Inc SAVA.OQ SAVA.O is expected to  show no change in quarterly revenue when it reports  results on N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF1GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","SAVA","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2577451592","title":"Cassava Sciences Inc - Case Against Wang Permanently Terminated - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577451592","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577451592?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:12","pubTimestamp":1761307925,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W52T7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","SAVA","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2577231055","title":"Cassava Sciences Inc. Files Initial Beneficial Ownership Statement for Director Dawn Carter","url":"https://stock-news.laohu8.com/highlight/detail?id=2577231055","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577231055?lang=en_us&edition=fundamental","pubTime":"2025-10-23 06:12","pubTimestamp":1761171145,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Dawn Carter Bir as the beneficial owner in the role of Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL57syqm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4585","BK4007","BK4588","SAVA"],"gpt_icon":0},{"id":"2577364513","title":"Cassava Sciences appoints Dawn Bir to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2577364513","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577364513?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:16","pubTimestamp":1761135396,"startTime":"0","endTime":"0","summary":"Cassava Sciences (SAVA) announced the appointment of Dawn Bir to its Board of Directors. Dawn Bir is a seasoned biopharmaceutical executive and boa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cassava-sciences-appoints-dawn-bir-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cassava-sciences-appoints-dawn-bir-to-board-of-directors-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","BK4547","SAVA","BK4585"],"gpt_icon":0},{"id":"2577036908","title":"Cassava Sciences Appoints Dawn C. Bir to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2577036908","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577036908?lang=en_us&edition=fundamental","pubTime":"2025-10-22 20:00","pubTimestamp":1761134432,"startTime":"0","endTime":"0","summary":"Cassava Sciences Inc. has appointed Dawn C. Bir to its Board of Directors. Bir brings extensive experience from leadership roles at companies including Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics. The company is preparing to begin its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire  on October 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL9ZtKDk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","BK4588","IE00B894F039.SGD","BK4533","LU2095319765.USD","GERN","LU0314104364.USD","BK4139","LU2210149790.SGD","LU0234570918.USD","IE00BGHQF748.EUR","BIIB","NDAQ","BK4532","IE00B3QW5Z07.USD","BK4547","LU0109394709.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0889565916.HKD","SLNO","BK4007","IE00B19Z9P08.USD","SAVA","LU0320765992.SGD","BK4585","LU2210150020.SGD","BK4112"],"gpt_icon":0},{"id":"2575297476","title":"Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2575297476","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575297476?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:01","pubTimestamp":1760443282,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on October 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL7dlxmq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","LU0314104364.USD","BK4547","IE00B3QW5Z07.USD","BK4007","LXRX","LU2210150020.SGD","BK4112","BK4585","SAVA","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cassavasciences.com","stockEarnings":[{"period":"1week","weight":-0.0815},{"period":"1month","weight":-0.1012},{"period":"3month","weight":0.3886},{"period":"6month","weight":0.4293},{"period":"1year","weight":0.0502},{"period":"ytd","weight":0.2415}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.56,"avgChangeRate":0.149543},{"month":2,"riseRate":0.44,"avgChangeRate":0.027406},{"month":3,"riseRate":0.44,"avgChangeRate":0.008402},{"month":4,"riseRate":0.6,"avgChangeRate":0.05975},{"month":5,"riseRate":0.44,"avgChangeRate":0.038503},{"month":6,"riseRate":0.44,"avgChangeRate":-0.019669},{"month":7,"riseRate":0.48,"avgChangeRate":0.007146},{"month":8,"riseRate":0.5,"avgChangeRate":0.01628},{"month":9,"riseRate":0.615385,"avgChangeRate":0.114687},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.039373},{"month":11,"riseRate":0.576923,"avgChangeRate":-0.009282},{"month":12,"riseRate":0.346154,"avgChangeRate":0.027391}],"exchange":"NASDAQ","name":"Cassava Sciences Inc","nameEN":"Cassava Sciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cassava Sciences Inc,SAVA,Cassava Sciences Inc股票,Cassava Sciences Inc股票老虎,Cassava Sciences Inc股票老虎国际,Cassava Sciences Inc行情,Cassava Sciences Inc股票行情,Cassava Sciences Inc股价,Cassava Sciences Inc股市,Cassava Sciences Inc股票价格,Cassava Sciences Inc股票交易,Cassava Sciences Inc股票购买,Cassava Sciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cassava Sciences Inc(SAVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cassava Sciences Inc(SAVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction